PLoS By Category | Recent PLoS Articles

Diabetes and Endocrinology - Oncology - Urology


Inhibition of Glycogen Synthase Kinase-3ß Counteracts Ligand-Independent Activity of the Androgen Receptor in Castration Resistant Prostate Cancer
Published: Thursday, September 29, 2011
Author: Stefanie V. Schütz et al.

by Stefanie V. Schütz, Andres J. Schrader, Friedemann Zengerling, Felicitas Genze, Marcus V. Cronauer, Mark Schrader

In order to generate genomic signals, the androgen receptor (AR) has to be transported into the nucleus upon androgenic stimuli. However, there is evidence from in vitro experiments that in castration-resistant prostate cancer (CRPC) cells the AR is able to translocate into the nucleus in a ligand-independent manner. The recent finding that inhibition of the glycogen-synthase-kinase 3ß (GSK-3ß) induces a rapid nuclear export of the AR in androgen-stimulated prostate cancer cells prompted us to analyze the effects of a GSK-3ß inhibition in the castration-resistant LNCaP sublines C4-2 and LNCaP-SSR. Both cell lines exhibit high levels of nuclear AR in the absence of androgenic stimuli. Exposure of these cells to the maleimide SB216763, a potent GSK-3ß inhibitor, resulted in a rapid nuclear export of the AR even under androgen-deprived conditions. Moreover, the ability of C4-2 and LNCaP-SSR cells to grow in the absence of androgens was diminished after pharmacological inhibition of GSK-3ß in vitro. The ability of SB216763 to modulate AR signalling and function in CRPC in vivo was additionally demonstrated in a modified chick chorioallantoic membrane xenograft assay after systemic delivery of SB216763. Our data suggest that inhibition of GSK-3ß helps target the AR for export from the nucleus thereby diminishing the effects of mislocated AR in CRPC cells. Therefore, inhibition of GSK-3ß could be an interesting new strategy for the treatment of CRPC.
  More...

 
//-->